IDEX CORP /DE/ - Quarter Report: 2010 March (Form 10-Q)
Table of Contents
UNITED STATES SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
Form 10-Q
þ
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |
For the quarterly period ended
March 31, 2010 |
||
OR
|
||
o
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Commission file number 1-10235
IDEX CORPORATION
(Exact Name of Registrant as
Specified in its Charter)
Delaware (State or other jurisdiction of incorporation or organization) |
36-3555336 (I.R.S. Employer Identification No.) |
|
630 Dundee Road, Northbrook, Illinois (Address of principal executive offices) |
60062 (Zip Code) |
Registrants telephone number:
(847) 498-7070
Indicate by check mark whether the registrant: (1) has
filed all reports required to be filed by Section 13 or
15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has
been subject to such filing requirements for the past
90 days.
Yes þ No o
Indicate by check mark whether the registrant has submitted
electronically and posted on its corporate Web site, if any,
every Interactive Data File required to be submitted and posted
pursuant to Rule 405 of
Regulation S-T
during the preceding 12 months (or for such shorter period
that the registrant was required to submit and post such files).
Yes o No o
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated
filer, or a smaller reporting company. See the definitions of
large accelerated filer, accelerated
filer and smaller reporting company in
Rule 12b-2
of the Exchange Act. (Check one):
Large accelerated filer þ | Accelerated filer o | Non-accelerated filer o | Smaller reporting company o |
(Do not check if a smaller reporting company)
Indicate by check mark whether the registrant is a shell company
(as defined in
Rule 12b-2
of the Exchange Act).
Yes o No þ
Number of shares of common stock of IDEX Corporation outstanding
as of April 29, 2010: 81,222,963 (net of treasury shares).
TABLE OF
CONTENTS
Table of Contents
PART I.
FINANCIAL INFORMATION
Item 1. | Financial Statements. |
IDEX
CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands except share and per share amounts)
(unaudited)
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands except share and per share amounts)
(unaudited)
March 31, 2010 | December 31, 2009 | |||||||
ASSETS
|
||||||||
Current assets
|
||||||||
Cash and cash equivalents
|
$ | 71,388 | $ | 73,526 | ||||
Receivables, less allowance for doubtful accounts of $6,135 at
March 31, 2010 and $6,160 at December 31, 2009
|
206,387 | 183,178 | ||||||
Inventories net
|
166,211 | 159,463 | ||||||
Other current assets
|
40,847 | 35,545 | ||||||
Total current assets
|
484,833 | 451,712 | ||||||
Property, plant and equipment net
|
173,774 | 178,283 | ||||||
Goodwill
|
1,163,320 | 1,180,445 | ||||||
Intangible assets net
|
271,551 | 281,354 | ||||||
Other noncurrent assets
|
7,061 | 6,363 | ||||||
Total assets
|
$ | 2,100,539 | $ | 2,098,157 | ||||
LIABILITIES AND SHAREHOLDERS EQUITY | ||||||||
Current liabilities
|
||||||||
Trade accounts payable
|
$ | 81,386 | $ | 73,020 | ||||
Accrued expenses
|
99,985 | 98,730 | ||||||
Short-term borrowings
|
2,609 | 8,346 | ||||||
Dividends payable
|
| 9,586 | ||||||
Total current liabilities
|
183,980 | 189,682 | ||||||
Long-term borrowings
|
383,098 | 391,754 | ||||||
Deferred income taxes
|
148,776 | 148,806 | ||||||
Other noncurrent liabilities
|
93,641 | 99,811 | ||||||
Total liabilities
|
809,495 | 830,053 | ||||||
Commitment and contingencies
|
||||||||
Shareholders equity
|
||||||||
Preferred stock:
|
||||||||
Authorized: 5,000,000 shares, $.01 per share par value;
Issued: None
|
| | ||||||
Common stock:
|
||||||||
Authorized: 150,000,000 shares, $.01 per share par value
Issued: 83,848,525 shares at March 31, 2010 and
83,510,320 shares at December 31, 2009
|
838 | 835 | ||||||
Additional paid-in capital
|
408,205 | 401,570 | ||||||
Retained earnings
|
933,602 | 896,977 | ||||||
Treasury stock at cost: 2,540,052 shares at March 31,
2010 and December 31, 2009
|
(56,706 | ) | (56,706 | ) | ||||
Accumulated other comprehensive income
|
5,105 | 25,428 | ||||||
Total shareholders equity
|
1,291,044 | 1,268,104 | ||||||
Total liabilities and shareholders equity
|
$ | 2,100,539 | $ | 2,098,157 | ||||
See Notes to Condensed Consolidated Financial Statements.
1
Table of Contents
IDEX
CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands except per share amounts)
(unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands except per share amounts)
(unaudited)
Three Months Ended |
||||||||
March 31, | ||||||||
2010 | 2009 | |||||||
Net sales
|
$ | 355,598 | $ | 326,613 | ||||
Cost of sales
|
208,057 | 203,419 | ||||||
Gross profit
|
147,541 | 123,194 | ||||||
Selling, general and administrative expenses
|
87,781 | 81,782 | ||||||
Restructuring expenses
|
1,867 | 2,251 | ||||||
Operating income
|
57,893 | 39,161 | ||||||
Other income (expense) net
|
254 | (191 | ) | |||||
Interest expense
|
3,434 | 4,821 | ||||||
Income before income taxes
|
54,713 | 34,149 | ||||||
Provision for income taxes
|
18,088 | 11,544 | ||||||
Net income
|
$ | 36,625 | $ | 22,605 | ||||
Basic earnings per common share
|
$ | 0.45 | $ | 0.28 | ||||
Diluted earnings per common share
|
$ | 0.45 | $ | 0.28 | ||||
Share data:
|
||||||||
Basic weighted average common shares outstanding
|
80,080 | 79,513 | ||||||
Diluted weighted average common shares outstanding
|
81,509 | 80,219 |
See Notes to Condensed Consolidated Financial Statements.
2
Table of Contents
IDEX
CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS EQUITY
(in thousands except share amounts)
(unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS EQUITY
(in thousands except share amounts)
(unaudited)
Accumulated Other Comprehensive Income | ||||||||||||||||||||||||||||
Net |
||||||||||||||||||||||||||||
Actuarial |
||||||||||||||||||||||||||||
Losses |
||||||||||||||||||||||||||||
and Prior |
||||||||||||||||||||||||||||
Service |
||||||||||||||||||||||||||||
Costs on |
||||||||||||||||||||||||||||
Pensions |
||||||||||||||||||||||||||||
and Other |
Cumulative |
|||||||||||||||||||||||||||
Common Stock |
Post- |
Unrealized Losses |
||||||||||||||||||||||||||
and Additional |
Cumulative |
Retirement |
on Derivatives |
Total |
||||||||||||||||||||||||
Paid-In |
Retained |
Translation |
Benefit |
Designated as Cash |
Treasury |
Shareholders |
||||||||||||||||||||||
Capital | Earnings | Adjustment | Plans | Flow Hedges | Stock | Equity | ||||||||||||||||||||||
Balance, December 31, 2009
|
$ | 402,405 | $ | 896,977 | $ | 59,399 | $ | (27,258 | ) | $ | (6,713 | ) | $ | (56,706 | ) | $ | 1,268,104 | |||||||||||
Net income
|
| 36,625 | | | | | 36,625 | |||||||||||||||||||||
Other comprehensive income, net of tax:
|
||||||||||||||||||||||||||||
Cumulative translation adjustment
|
| | (22,641 | ) | | | | (22,641 | ) | |||||||||||||||||||
Amortization of retirement obligations
|
| | | 743 | | | 743 | |||||||||||||||||||||
Net change on derivatives designated as cash flow hedges
|
| | | | 1,575 | | 1,575 | |||||||||||||||||||||
Other comprehensive income
|
| | | | | | (20,323 | ) | ||||||||||||||||||||
Comprehensive income
|
| | | | | | 16,302 | |||||||||||||||||||||
Issuance of 354,496 shares of common stock from issuance of
unvested shares, exercise of stock options and deferred
compensation plans, net of tax benefit
|
1,890 | | | | | | 1,890 | |||||||||||||||||||||
Share-based compensation
|
4,748 | | | | | | 4,748 | |||||||||||||||||||||
Balance, March 31, 2010
|
$ | 409,043 | $ | 933,602 | $ | 36,758 | $ | (26,515 | ) | $ | (5,138 | ) | $ | (56,706 | ) | $ | 1,291,044 | |||||||||||
See Notes to Condensed Consolidated Financial Statements.
3
Table of Contents
IDEX
CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
Three Months |
||||||||
Ended |
||||||||
March 31, | ||||||||
2010 | 2009 | |||||||
Cash flows from operating activities
|
||||||||
Net income
|
$ | 36,625 | $ | 22,605 | ||||
Adjustments to reconcile net income to net cash provided by
operating activities:
|
||||||||
Depreciation and amortization
|
8,016 | 7,591 | ||||||
Amortization of intangible assets
|
6,268 | 6,003 | ||||||
Amortization of debt issuance expenses
|
104 | 73 | ||||||
Stock-based compensation expense
|
4,748 | 5,545 | ||||||
Deferred income taxes
|
1,664 | 6,327 | ||||||
Excess tax benefit from stock-based compensation
|
(554 | ) | (640 | ) | ||||
Changes in:
|
||||||||
Receivables
|
(26,271 | ) | (5,025 | ) | ||||
Inventories
|
(9,496 | ) | 213 | |||||
Trade accounts payable
|
10,320 | (721 | ) | |||||
Accrued expenses
|
3,417 | (18,024 | ) | |||||
Other net
|
(7,710 | ) | (6,304 | ) | ||||
Net cash flows provided by operating activities
|
27,131 | 17,643 | ||||||
Cash flows from investing activities
|
||||||||
Additions to property, plant and equipment
|
(7,548 | ) | (4,852 | ) | ||||
Proceeds from fixed assets disposals
|
| 1,610 | ||||||
Other net
|
| 250 | ||||||
Net cash flows used in investing activities
|
(7,548 | ) | (2,992 | ) | ||||
Cash flows from financing activities
|
||||||||
Borrowings under credit facilities
|
| 32,310 | ||||||
Payments under credit facilities
|
(11,077 | ) | (37,271 | ) | ||||
Dividends paid
|
(9,697 | ) | (9,523 | ) | ||||
Proceeds from stock option exercises
|
1,197 | 1,116 | ||||||
Excess tax benefit from stock-based compensation
|
554 | 640 | ||||||
Other net
|
| (204 | ) | |||||
Net cash flows used in financing activities
|
(19,023 | ) | (12,932 | ) | ||||
Effect of exchange rate changes on cash and cash equivalents
|
(2,698 | ) | 25 | |||||
Net increase (decrease) in cash
|
(2,138 | ) | 1,744 | |||||
Cash and cash equivalents at beginning of year
|
73,526 | 61,353 | ||||||
Cash and cash equivalents at end of period
|
$ | 71,388 | $ | 63,097 | ||||
Supplemental cash flow information
|
||||||||
Cash paid for:
|
||||||||
Interest
|
$ | 3,572 | $ | 5,119 | ||||
Income taxes
|
5,843 | 8,143 | ||||||
Significant non-cash activities:
|
||||||||
Issuance of unvested shares
|
182 | |
See Notes to Condensed Consolidated Financial Statements.
4
Table of Contents
IDEX
CORPORATION AND SUBSIDIARIES
(unaudited)
1. | Basis of Presentation and Significant Accounting Policies |
The Condensed Consolidated Financial Statements of IDEX
Corporation (IDEX or the Company) have
been prepared in accordance with the instructions to
Form 10-Q
under the Securities Exchange Act of 1934, as amended. The
statements are unaudited but include all adjustments, consisting
only of recurring items, except as noted, which the Company
considers necessary for a fair presentation of the information
set forth herein. The results of operations for the three months
ended March 31, 2010 are not necessarily indicative of the
results to be expected for the entire year.
The condensed consolidated financial statements and
Managements Discussion and Analysis of Financial Condition
and Results of Operations should be read in conjunction with the
Companys Annual Report on
Form 10-K
for the fiscal year ended December 31, 2009.
2. | Restructuring |
The Company has recorded restructuring costs as a result of cost
reduction efforts and facility closings. Accruals have been
recorded based on these costs and primarily consist of employee
termination benefits. We record expenses for employee
termination benefits based on the guidance of Accounting
Standards Codification (ASC) 420, Exit or
Disposal Cost Obligations. These expenses are included in
Restructuring expenses in the Consolidated Statements of
Operations while the related restructuring accruals are included
in Accrued expenses in our Consolidated Balance Sheets.
During the three months ended March 31, 2010, the Company
recorded an additional $1.9 million of pre-tax
restructuring expenses related to our 2009 restructuring
initiative for employee severance related to employee reductions
across various functional areas as well as facility closures
resulting from the Companys cost savings initiatives. In
the first three months of 2009, the Company recorded pre-tax
restructuring expenses totaling $2.3 million related to
this same initiative. The 2009 initiative has included severance
benefits for over 500 employees. This initiative is
expected to be completed by the end of 2010 with an expected
additional total cost of $2.0-$3.0 million during the
remainder of 2010.
Pre-tax restructuring expenses, by segment, for the three months
ended March 31, 2010 were as follows:
Severance |
||||||||||||
Costs | Exit Costs | Total | ||||||||||
(in thousands) | ||||||||||||
Fluid & Metering Technologies
|
$ | 351 | $ | 18 | $ | 369 | ||||||
Health & Science Technologies
|
509 | 54 | 563 | |||||||||
Dispensing Equipment
|
115 | | 115 | |||||||||
Fire & Safety/Diversified Products
|
352 | | 352 | |||||||||
Corporate/Other
|
396 | 72 | 468 | |||||||||
Total restructuring costs
|
$ | 1,723 | $ | 144 | $ | 1,867 | ||||||
5
Table of Contents
IDEX
CORPORATION AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Pre-tax restructuring expenses, by segment, for the three months
ended March 31, 2009 were as follows:
Severance |
||||||||||||
Costs |
||||||||||||
(Reversals) | Exit Costs | Total | ||||||||||
(in thousands) | ||||||||||||
Fluid & Metering Technologies
|
$ | 812 | $ | 288 | $ | 1,100 | ||||||
Health & Science Technologies
|
657 | 191 | 848 | |||||||||
Dispensing Equipment
|
(311 | ) | 381 | 70 | ||||||||
Fire & Safety/Diversified Products
|
23 | | 23 | |||||||||
Corporate/Other
|
160 | 50 | 210 | |||||||||
Total restructuring costs
|
$ | 1,341 | $ | 910 | $ | 2,251 | ||||||
Restructuring accruals of $4.2 million and
$6.9 million as of March 31, 2010 and
December 31, 2009, respectively, are reflected in Accrued
expenses in our Condensed Consolidated Balance Sheets as follows
(in thousands):
Balance at January 1, 2010
|
$ | 6,878 | ||
Restructuring costs
|
1,867 | |||
Payments/Utilization
|
(4,511 | ) | ||
Balance at March 31, 2010
|
$ | 4,234 | ||
3. | Business Segments |
The Company consists of four reportable business segments:
Fluid & Metering Technologies, Health &
Science Technologies, Dispensing Equipment and Fire &
Safety/Diversified Products.
The Fluid & Metering Technologies Segment designs,
produces and distributes positive displacement pumps, flow
meters, injectors, and other fluid-handling pump modules and
systems and provides flow monitoring and other services for
water and wastewater. The Health & Science
Technologies Segment designs, produces and distributes a wide
range of precision fluidics solutions, including very high
precision, low-flow rate pumping solutions required in
analytical instrumentation, clinical diagnostics and drug
discovery, high performance molded and extruded biocompatible
medical devices and implantables, air compressors used in
medical, dental and industrial applications, and precision gear
and peristaltic pump technologies that meet exacting OEM
specifications. The Dispensing Equipment Segment produces
precision equipment for dispensing, metering and mixing
colorants, paints, and hair colorants and other personal care
products used in a variety of retail and commercial businesses
around the world. The Fire & Safety/Diversified
Products Segment produces firefighting pumps and controls,
rescue tools, lifting bags and other components and systems for
the fire and rescue industry, and engineered stainless steel
banding and clamping devices used in a variety of industrial and
commercial applications.
6
Table of Contents
IDEX
CORPORATION AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Information on the Companys business segments is presented
below, based on the nature of products and services offered. The
Company evaluates performance based on several factors, of which
operating income is the primary financial measure. Intersegment
sales are accounted for at fair value as if the sales were to
third parties.
Three Months |
||||||||
Ended |
||||||||
March 31, | ||||||||
2010 | 2009 | |||||||
(In thousands) | ||||||||
Net sales:
|
||||||||
Fluid & Metering Technologies:
|
||||||||
External customers
|
$ | 172,709 | $ | 156,731 | ||||
Intersegment sales
|
168 | 287 | ||||||
Total group sales
|
172,877 | 157,018 | ||||||
Health & Science Technologies:
|
||||||||
External customers
|
85,982 | 72,028 | ||||||
Intersegment sales
|
1,540 | 2,160 | ||||||
Total group sales
|
87,522 | 74,188 | ||||||
Dispensing Equipment:
|
||||||||
External customers
|
33,538 | 32,873 | ||||||
Intersegment sales
|
16 | | ||||||
Total group sales
|
33,554 | 32,873 | ||||||
Fire & Safety/Diversified Products:
|
||||||||
External customers
|
63,369 | 64,981 | ||||||
Intersegment sales
|
32 | 1 | ||||||
Total group sales
|
63,401 | 64,982 | ||||||
Intersegment elimination
|
(1,756 | ) | (2,448 | ) | ||||
Total net sales
|
$ | 355,598 | $ | 326,613 | ||||
Operating income:
|
||||||||
Fluid & Metering Technologies
|
$ | 32,140 | $ | 22,618 | ||||
Health & Science Technologies
|
18,552 | 9,850 | ||||||
Dispensing Equipment
|
6,639 | 3,979 | ||||||
Fire & Safety/Diversified Products
|
13,071 | 13,571 | ||||||
Corporate office and other
|
(12,509 | ) | (10,857 | ) | ||||
Total operating income
|
$ | 57,893 | $ | 39,161 | ||||
4. | Earnings Per Common Share |
Earnings per common share (EPS) are computed by
dividing net income by the weighted average number of shares of
common stock (basic) plus common stock equivalents outstanding
(diluted) during the period. Common stock equivalents consist of
stock options, which have been included in the calculation of
weighted average shares outstanding using the treasury stock
method, unvested shares, and shares issuable in connection with
certain deferred compensation agreements (DCUs).
7
Table of Contents
IDEX
CORPORATION AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
ASC 260 Earnings Per Share, (ASC 260)
concludes that all outstanding unvested share-based payment
awards that contain rights to nonforfeitable dividends
participate in undistributed earnings with common shareholders.
If awards are considered participating securities, the Company
is required to apply the two-class method of computing basic and
diluted earnings per share. The Company has determined that its
outstanding unvested shares are participating securities.
Accordingly, earnings per common share are computed using the
two-class method prescribed by ASC 260. Net income
attributable to common shareholders was reduced by
$0.4 million and $0.2 million for the three months
ended March 31, 2010 and 2009, respectively.
Basic weighted average shares reconciles to diluted weighted
average shares as follows:
Three |
||||||||
Months |
||||||||
Ended March 31, | ||||||||
2010 | 2009 | |||||||
(in thousands) | ||||||||
Basic weighted average common shares outstanding
|
80,080 | 79,513 | ||||||
Dilutive effect of stock options, unvested shares, and DCUs
|
1,429 | 706 | ||||||
Diluted weighted average common shares outstanding
|
81,509 | 80,219 | ||||||
Options to purchase approximately 3.0 million and
4.4 million shares of common stock as of March 31,
2010 and 2009, respectively, were not included in the
computation of diluted EPS because the exercise price was
greater than the average market price of the Companys
common stock and, therefore, the effect of their inclusion would
be antidilutive.
5. | Inventories |
The components of inventories as of March 31, 2010 and
December 31, 2009 were:
March 31, |
December 31, |
|||||||
2010 | 2009 | |||||||
(In thousands) | ||||||||
Raw materials and component parts
|
$ | 115,714 | $ | 113,777 | ||||
Work-in-process
|
23,225 | 20,669 | ||||||
Finished goods
|
46,493 | 43,626 | ||||||
Total
|
185,432 | 178,072 | ||||||
Less inventory reserves
|
19,221 | 18,609 | ||||||
Total
inventories-net
|
$ | 166,211 | $ | 159,463 | ||||
Inventories are stated at the lower of cost or market. Cost,
which includes material, labor, and factory overhead, is
determined on a FIFO basis.
8
Table of Contents
IDEX
CORPORATION AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
6. | Goodwill and Intangible Assets |
The changes in the carrying amount of goodwill for the three
months ended March 31, 2010, by reportable segment, were as
follows:
Fluid & |
Health & |
Fire & Safety/ |
||||||||||||||||||
Metering |
Science |
Dispensing |
Diversified |
|||||||||||||||||
Technologies | Technologies | Equipment | Products | Total | ||||||||||||||||
(In thousands) | ||||||||||||||||||||
Balance at December 31, 2009
|
$ | 533,979 | $ | 392,379 | $ | 104,973 | $ | 149,114 | $ | 1,180,445 | ||||||||||
Foreign currency translation
|
(7,503 | ) | (855 | ) | (5,095 | ) | (3,672 | ) | (17,125 | ) | ||||||||||
Balance at March 31, 2010
|
$ | 526,476 | $ | 391,524 | $ | 99,878 | $ | 145,442 | $ | 1,163,320 | ||||||||||
ASC 350 Goodwill and Other Intangible Assets
requires that goodwill be tested for impairment at the reporting
unit level on an annual basis and between annual tests if an
event occurs or circumstances change that would more likely than
not reduce the fair value of the reporting unit below its
carrying value. Annually on October 31st, goodwill and
other acquired intangible assets with indefinite lives are
tested for impairment. The Company concluded that the fair value
of each of the reporting units was in excess of the carrying
value as of October 31, 2009. The Company did not consider
there to be any triggering event that would require an interim
impairment assessment, therefore none of the goodwill or other
acquired intangible assets with indefinite lives were tested for
impairment during the three months ended March 31, 2010.
The following table provides the gross carrying value and
accumulated amortization for each major class of intangible
asset at March 31, 2010 and December 31, 2009:
At March 31, 2010 | At December 31, 2009 | |||||||||||||||||||||||||||
Gross |
Weighted |
Gross |
||||||||||||||||||||||||||
Carrying |
Accumulated |
Average |
Carrying |
Accumulated |
||||||||||||||||||||||||
Amount | Amortization | Net | Life | Amount | Amortization | Net | ||||||||||||||||||||||
Amortizable intangible assets:
|
||||||||||||||||||||||||||||
Patents
|
$ | 9,762 | $ | (4,534 | ) | $ | 5,228 | 11 | $ | 9,914 | $ | (4,289 | ) | $ | 5,625 | |||||||||||||
Trade names
|
62,623 | (11,029 | ) | 51,594 | 15 | 63,589 | (10,144 | ) | 53,445 | |||||||||||||||||||
Customer relationships
|
155,282 | (35,813 | ) | 119,469 | 12 | 157,890 | (32,422 | ) | 125,468 | |||||||||||||||||||
Non-compete agreements
|
4,239 | (3,470 | ) | 769 | 4 | 4,268 | (3,356 | ) | 912 | |||||||||||||||||||
Unpatented technology
|
35,450 | (6,907 | ) | 28,543 | 14 | 36,047 | (6,240 | ) | 29,807 | |||||||||||||||||||
Other
|
6,232 | (2,384 | ) | 3,848 | 10 | 6,236 | (2,239 | ) | 3,997 | |||||||||||||||||||
Total amortizable intangible assets
|
273,588 | (64,137 | ) | 209,451 | 277,944 | (58,690 | ) | 219,254 | ||||||||||||||||||||
Banjo trade name
|
62,100 | | 62,100 | 62,100 | | 62,100 | ||||||||||||||||||||||
$ | 335,688 | $ | (64,137 | ) | $ | 271,551 | $ | 340,044 | $ | (58,690 | ) | $ | 281,354 | |||||||||||||||
The Banjo trade name is an indefinite lived intangible asset
which is tested for impairment on an annual basis or more
frequently if events or changes in circumstances indicate that
the asset might be impaired.
9
Table of Contents
IDEX
CORPORATION AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
7. | Accrued Expenses |
The components of accrued expenses as of March 31, 2010 and
December 31, 2009 were:
March 31, |
December 31, |
|||||||
2010 | 2009 | |||||||
(In thousands) | ||||||||
Payroll and related items
|
$ | 38,474 | $ | 39,315 | ||||
Management incentive compensation
|
5,885 | 12,157 | ||||||
Income taxes payable
|
14,844 | 3,757 | ||||||
Insurance
|
4,732 | 4,375 | ||||||
Warranty
|
4,754 | 4,383 | ||||||
Deferred revenue
|
3,090 | 4,480 | ||||||
Restructuring
|
4,234 | 6,878 | ||||||
Other
|
23,972 | 23,385 | ||||||
Total accrued expenses
|
$ | 99,985 | $ | 98,730 | ||||
8. | Borrowings |
Borrowings at March 31, 2010 and December 31, 2009
consisted of the following:
March 31, |
December 31, |
|||||||
2010 | 2009 | |||||||
(In thousands) | ||||||||
Credit Facility
|
$ | 290,359 | $ | 298,732 | ||||
Term Loan
|
90,000 | 95,000 | ||||||
Other borrowings
|
5,348 | 6,368 | ||||||
Total borrowings
|
385,707 | 400,100 | ||||||
Less current portion
|
2,609 | 8,346 | ||||||
Total long-term borrowings
|
$ | 383,098 | $ | 391,754 | ||||
The Company maintains a $600.0 million unsecured domestic,
multi-currency bank revolving credit facility (Credit
Facility), which expires on December 21, 2011. In
2008, the Credit Facility was amended to allow the Company to
designate certain foreign subsidiaries as designated borrowers.
Upon approval from the lenders, the designated borrowers were
allowed to receive loans under the Credit Facility. A designated
borrower sublimit was established as the lesser of the aggregate
commitments or $100.0 million. As of the amendment date,
Fluid Management Europe B.V., (FME) was approved by the lenders
as a designated borrower. On March 16, 2010, IDEX UK Ltd.
(IDEX UK) was approved by the lenders as a
designated borrower which will allow them to receive loans under
the Credit Facility. IDEX UK had no borrowings under the Credit
Facility as of March 31, 2010. FMEs borrowings under
the Credit Facility at March 31, 2010 and December 31,
2009 were $40.4 million (Euro 30.0 million) and
$48.7 million (Euro 34.0 million), respectively. As
the FME borrowings under the Credit Facility are Euro
denominated and the cash flows that will be used to make
payments of principal and interest are predominately denominated
in Euro, the Company does not anticipate any significant foreign
exchange gains or losses in servicing this debt.
At March 31, 2010 there was $290.4 million outstanding
under the Credit Facility and outstanding letters of credit
totaled approximately $7.1 million. The net available
borrowing under the Credit Facility as of March 31, 2010,
was approximately $302.5 million. Interest is payable
quarterly on the outstanding borrowings at the bank agents
reference rate. Interest on borrowings based on LIBOR plus an
applicable margin is payable on the maturity date of the
borrowing, or quarterly from the effective date for borrowings
exceeding three months. The applicable
10
Table of Contents
IDEX
CORPORATION AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
margin is based on the Companys senior, unsecured,
long-term debt rating and can range from 24 basis points to
50 basis points. Based on the Companys BBB rating at
March 31, 2010, the applicable margin was 40 basis
points. An annual Credit Facility fee, also based on the
Companys credit rating, is currently 10 basis points
and is payable quarterly.
At March 31, 2010 the Company had one interest rate
exchange agreement related to the Credit Facility. The interest
rate exchange agreement, expiring in January 2011, effectively
converted $250.0 million of floating-rate debt into
fixed-rate debt at an interest rate of 3.25%. The fixed rate
noted above is comprised of the fixed rate on the interest rate
exchange agreement and the Companys current margin of
40 basis points on the Credit Facility.
On April 18, 2008, the Company completed a
$100.0 million unsecured senior bank term loan agreement
(Term Loan) with covenants consistent with the
existing Credit Facility and a maturity on December 21,
2011. At March 31, 2010, there was $90.0 million
outstanding under the Term Loan. Interest under the Term Loan is
based on the bank agents reference rate or LIBOR plus an
applicable margin and is payable at the end of the selected
interest period, but at least quarterly. The applicable margin
is based on the Companys senior, unsecured, long-term debt
rating and can range from 45 to 100 basis points. Based on
the Companys current debt rating, the applicable margin is
80 basis points. The Term Loan requires a repayment of
$7.5 million in April 2011, with the remaining balance due
on December 21, 2011. The Company used the proceeds from
the Term Loan to pay down existing debt outstanding under the
Credit Facility.
At March 31, 2010 the Company had an interest rate exchange
agreement related to the Term Loan that expires December 2011.
With a current notional amount of $90.0 million, the
agreement effectively converted $100.0 million of
floating-rate debt into fixed-rate debt at an interest rate of
4.00%. The fixed rate is comprised of the fixed rate on the
interest rate exchange agreement and the Companys current
margin of 80 basis points on the Term Loan.
9. | Derivative Instruments |
The Company enters into cash flow hedges to reduce the exposure
to variability in certain expected future cash flows. The type
of cash flow hedges the Company enters into includes foreign
currency contracts and interest rate exchange agreements that
effectively convert a portion of floating-rate debt to
fixed-rate debt and are designed to reduce the impact of
interest rate changes on future interest expense.
The effective portion of gains or losses on interest rate
exchange agreements is reported in accumulated other
comprehensive income in shareholders equity and
reclassified into net income in the same period or periods in
which the hedged transaction affects net income. The remaining
gain or loss in excess of the cumulative change in the present
value of future cash flows or the hedged item, if any, is
recognized into net income during the period of change.
Fair values relating to derivative financial instruments reflect
the estimated amounts that the Company would receive or pay to
sell or buy the contracts based on quoted market prices of
comparable contracts at each balance sheet date.
At March 31, 2010, the Company had two interest rate
exchange agreements. The first interest rate exchange agreement,
expiring in January 2011, effectively converted
$250.0 million of floating-rate debt into fixed-rate debt
at an interest rate of 3.25%. The second interest rate exchange
agreement, expiring December 2011, with a current notional
amount of $90.0 million, effectively converted
$100.0 million of floating-rate debt into fixed-rate debt
at an interest rate of 4.00%. The fixed rate is comprised of the
fixed rate on the interest rate exchange agreements and the
Companys current margin of 40 basis points for the
Credit Facility and 80 basis points on the Term Loan.
Based on interest rates at March 31, 2010, approximately
$7.4 million of the amount included in accumulated other
comprehensive income in shareholders equity at
March 31, 2010 will be recognized to net income over the
next 12 months as the underlying hedged transactions are
realized.
11
Table of Contents
IDEX
CORPORATION AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The following table sets forth the fair value amounts of
derivative instruments held by the Company as of March 31,
2010 and December 31, 2009:
Fair Value-Liabilities | ||||||||||
March 31, |
December 31, |
|||||||||
2010 | 2009 | Balance Sheet Caption | ||||||||
(In thousands) | ||||||||||
Interest rate contracts
|
$ | 8,055 | $ | 10,497 | Other noncurrent liabilities |
The following table summarizes the net change recognized and the
amounts and location of income (expense) and gain (loss)
reclassified into income for interest rate contracts and foreign
currency contracts during the first three months of
March 31, 2010 and 2009:
Gain (Loss) Recognized in |
Expense |
|||||||||||||||||
Other |
and Loss |
|||||||||||||||||
Comprehensive |
Reclassified into |
|||||||||||||||||
Income | Income |
Income |
||||||||||||||||
2010 | 2009 | 2010 | 2009 | Statement Caption | ||||||||||||||
(In thousands) | ||||||||||||||||||
Interest rate contracts
|
$ | 116 | $ | (1,772 | ) | $ | (2,326 | ) | $ | (1,692 | ) | Interest expense | ||||||
Foreign exchange contracts
|
| (69 | ) | | (80 | ) | Sales |
10. | Fair Value Measurements |
ASC 820 Fair Value Measurements and Disclosures
defines fair value, provides guidance for measuring fair value
and requires certain disclosures. This standard discusses
valuation techniques, such as the market approach (comparable
market prices), the income approach (present value of future
income or cash flow), and the cost approach (cost to replace the
service capacity of an asset or replacement cost). The standard
utilizes a fair value hierarchy that prioritizes the inputs to
valuation techniques used to measure fair value into three broad
levels. The following is a brief description of those three
levels:
| Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities. | |
| Level 2: Inputs, other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. | |
| Level 3: Unobservable inputs that reflect the reporting entitys own assumptions. |
The following table summarizes the basis used to measure the
Companys financial assets and liabilities at fair value on
a recurring basis in the balance sheet at March 31, 2010
and December 31, 2009:
Basis of Fair Value Measurements | ||||||||||||||||
Balance at |
||||||||||||||||
March 31, 2010 | Level 1 | Level 2 | Level 3 | |||||||||||||
(In thousands) | ||||||||||||||||
Money market investment
|
$ | 8,115 | $ | 8,115 | | | ||||||||||
Interest rate exchange agreement
derivative financial instruments |
$ | 8,055 | | $ | 8,055 | |
12
Table of Contents
IDEX
CORPORATION AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Basis of Fair Value Measurements | ||||||||||||||||
Balance at |
||||||||||||||||
December 31, 2009 | Level 1 | Level 2 | Level 3 | |||||||||||||
(In thousands) | ||||||||||||||||
Money market investment
|
$ | 9,186 | $ | 9,186 | | | ||||||||||
Interest rate exchange agreement derivative financial instruments
|
$ | 10,497 | | $ | 10,497 | |
In determining the fair value of the Companys interest
rate exchange agreement derivatives, the Company uses a present
value of expected cash flows based on market observable interest
rate yield curves commensurate with the term of each instrument
and the credit default swap market to reflect the credit risk of
either the Company or the counterparty.
The carrying value of our cash and cash equivalents, accounts
receivable, accounts payable and accrued expenses approximates
their fair values because of the short term nature of these
instruments. At March 31, 2010, the fair value of our
Credit Facility and Term Loan, based on the current market rates
for debt with similar credit risk and maturity, was
approximately $370.3 million compared to the carrying value
of $380.4 million.
11. | Common and Preferred Stock |
At March 31, 2010 and December 31, 2009, the Company
had 150 million shares of authorized common stock, with a
par value of $.01 per share and 5 million shares of
preferred stock with a par value of $.01 per share. No preferred
stock was issued as of March 31, 2010 and December 31,
2009.
12. | Share-Based Compensation |
During the three months ending March 31, 2010, the Company
granted approximately 0.9 million stock options and
0.2 million unvested shares, respectively. During the three
months ending March 31, 2009, the Company granted
approximately 1.2 million stock options and
0.3 million unvested shares, respectively.
Total compensation cost for stock options is as follows:
Three Months |
||||||||
Ended March 31, | ||||||||
2010 | 2009 | |||||||
(In thousands) | ||||||||
Cost of goods sold
|
$ | 258 | $ | 324 | ||||
Selling, general and administrative expenses
|
1,957 | 2,247 | ||||||
Total expense before income taxes
|
2,215 | 2,571 | ||||||
Income tax benefit
|
(700 | ) | (843 | ) | ||||
Total expense after income taxes
|
$ | 1,515 | $ | 1,728 | ||||
13
Table of Contents
IDEX
CORPORATION AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Total compensation cost for unvested shares is as follows:
Three Months |
||||||||
Ended March 31, | ||||||||
2010 | 2009 | |||||||
(In thousands) | ||||||||
Cost of goods sold
|
$ | 127 | $ | 62 | ||||
Selling, general and administrative expenses
|
2,406 | 2,912 | ||||||
Total expense before income taxes
|
2,533 | 2,974 | ||||||
Income tax benefit
|
(567 | ) | (472 | ) | ||||
Total expense after income taxes
|
$ | 1,966 | $ | 2,502 | ||||
Classification of stock compensation cost within the
Consolidated Statements of Operations is consistent with
classification of cash compensation for the same employees and
$0.1 million of compensation cost was capitalized as part
of inventory.
As of March 31, 2010, there was $15.8 million of total
unrecognized compensation cost related to stock options that is
expected to be recognized over a weighted-average period of
1.5 years, and $16.1 million of total unrecognized
compensation cost related to unvested shares that is expected to
be recognized over a weighted-average period of 1.2 years.
13. | Retirement Benefits |
The Company sponsors several qualified and nonqualified defined
benefit and defined contribution pension plans and other
postretirement plans for its employees. The following tables
provide the components of net periodic benefit cost for its
major defined benefit plans and its other postretirement plans.
Pension Benefits | ||||||||||||||||
Three Months Ended March 31, | ||||||||||||||||
2010 | 2009 | |||||||||||||||
U.S. | Non-U.S. | U.S. | Non-U.S. | |||||||||||||
(In thousands) | ||||||||||||||||
Service cost
|
$ | 469 | $ | 184 | $ | 425 | $ | 192 | ||||||||
Interest cost
|
1,140 | 552 | 1,109 | 493 | ||||||||||||
Expected return on plan assets
|
(1,108 | ) | (83 | ) | (913 | ) | (179 | ) | ||||||||
Net amortization
|
1,127 | 76 | 1,218 | 86 | ||||||||||||
Net periodic benefit cost
|
$ | 1,628 | $ | 729 | $ | 1,839 | $ | 592 | ||||||||
Other Benefits | ||||||||
Three Months Ended |
||||||||
March 31, | ||||||||
2010 | 2009 | |||||||
(In thousands) | ||||||||
Service cost
|
$ | 130 | $ | 146 | ||||
Interest cost
|
259 | 337 | ||||||
Net amortization
|
(99 | ) | 12 | |||||
Net periodic benefit cost
|
$ | 290 | $ | 495 | ||||
The Company previously disclosed in its financial statements for
the year ended December 31, 2009, that it expected to
contribute approximately $4.7 million to these pension
plans and $1.0 million to its other postretirement
14
Table of Contents
IDEX
CORPORATION AND SUBSIDIARIES
NOTES TO
CONDENSED CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
benefit plans in 2010. As of March 31, 2010,
$1.3 million of contributions have been made to the pension
plans and $0.1 million have been made to its other
postretirement benefit plans. The Company presently anticipates
contributing up to an additional $4.3 million in 2010 to
fund these pension plans and other postretirement benefit plans.
In March of 2010 the United States enacted two new laws relating
to healthcare. The enactment of the Patient Protection and
Affordable Care Act and the Health Care and Education
Reconciliation Act of 2010 has resulted in comprehensive health
care reform. The Company is currently evaluating the
requirements and effect of this new legislation and does not
expect it to have a material impact on the consolidated
financial position, results of operations or cash flows of the
Company.
14. | Legal Proceedings |
The Company is party to various legal proceedings arising in the
ordinary course of business, none of which are expected to have
a material adverse effect on its business, financial condition,
results of operations or cash flows.
15. | Income Taxes |
The Companys provision for income taxes is based upon
estimated annual tax rates for the year applied to federal,
state and foreign income. The provision for income taxes
increased to $18.1 million in the first quarter of 2010
from $11.5 million in the first quarter of 2009. The
effective tax rate decreased to 33.1% for the first quarter of
2010 compared to 33.8% in the first quarter of 2009 due to the
mix of global pre-tax income among jurisdictions.
The Company and its subsidiaries file income tax returns in the
U.S. federal jurisdiction, and various state and foreign
jurisdictions. Due to the potential for resolution of federal,
state and foreign examinations, and the expiration of various
statutes of limitation, it is reasonably possible that the
Companys gross unrecognized tax benefits balance may
change within the next twelve months by a range of zero to
$0.6 million.
16. | Subsequent Events |
On April 15, 2010, the Company acquired Seals, Ltd
(Seals) for cash consideration of approximately
$54.0 million (£35 million). Seals, consisting of
the Polymer Engineering and Perlast divisions, is a leading
provider of proprietary high performance seals and advanced
sealing solutions for a diverse range of global industries,
including analytical instrumentation, semiconductor/solar and
process technologies. Seals Polymer Engineering division
focuses on sealing solutions for hazardous duty applications.
The Perlast division produces highly engineered seals for
analytical instrumentation, pharmaceutical, electronics, and
food applications. Headquartered in Blackburn, England, Seals
has annual revenues of approximately $32.0 million
(£21 million). Seals will operate as part of the
Health and Science Technologies segment.
On April 15, 2010, the Company entered into a forward
starting interest rate swap with a notional amount of
$300.0 million and an effective date of December 8,
2010 whereby the Company will pay fixed interest and will
receive floating rate interest based on LIBOR through the
termination date of December 8, 2020. This swap was entered
into in anticipation of the expected issuance of
$300.0 million of new debt during the fourth quarter of
2010 and is designed to lock in the current market interest rate.
15
Table of Contents
Item 2. | Managements Discussion and Analysis of Financial Condition and Results of Operations. |
Cautionary
Statement Under the Private Securities Litigation Reform
Act
The Historical Overview and the Liquidity and
Capital Resources sections of this managements
discussion and analysis of our financial condition and results
of operations contain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Exchange Act of 1934, as
amended. These statements may relate to, among other things,
operating results and are indicated by words or phrases such as
expects, should, will, and
similar words or phrases. These statements are subject to
inherent uncertainties and risks that could cause actual results
to differ materially from those anticipated at the date of this
filing. The risks and uncertainties include, but are not limited
to, IDEX Corporations (IDEX or the
Company) ability to integrate and operate acquired
businesses on a profitable basis and other risks and
uncertainties identified under the heading Risk
Factors included in item 1A of the Companys
Annual Report on
Form 10-K
for the year ended December 31, 2009 and information
contained in subsequent periodic reports filed by IDEX with the
Securities and Exchange Commission. Investors are cautioned not
to rely unduly on forward-looking statements when evaluating the
information presented here.
Historical
Overview
IDEX Corporation is an applied solutions company specializing in
fluid and metering technologies, health and science
technologies, dispensing equipment, and fire, safety and other
diversified products built to its customers
specifications. Our products are sold in niche markets to a wide
range of industries throughout the world. Accordingly, our
businesses are affected by levels of industrial activity and
economic conditions in the U.S. and in other countries
where we do business and by the relationship of the
U.S. dollar to other currencies. Levels of capacity
utilization and capital spending in certain industries and
overall industrial activity are among the factors that influence
the demand for our products.
The Company consists of four reportable segments:
Fluid & Metering Technologies, Health &
Science Technologies, Dispensing Equipment and Fire &
Safety/Diversified Products.
The Fluid & Metering Technologies Segment designs,
produces and distributes positive displacement pumps, flow
meters, injectors, and other fluid-handling pump modules and
systems and provides flow monitoring and other services for
water and wastewater. The Health & Science
Technologies Segment designs, produces and distributes a wide
range of precision fluidics solutions, including very high
precision, low-flow rate pumping solutions required in
analytical instrumentation, clinical diagnostics and drug
discovery, high performance molded and extruded biocompatible
medical devices and implantables, air compressors used in
medical, dental and industrial applications, and precision gear
and peristaltic pump technologies that meet exacting OEM
specifications. The Dispensing Equipment Segment produces
precision equipment for dispensing, metering and mixing
colorants, paints, and hair colorants and other personal care
products used in a variety of retail and commercial businesses
around the world. The Fire & Safety/Diversified
Products Segment produces firefighting pumps and controls,
rescue tools, lifting bags and other components and systems for
the fire and rescue industry, and engineered stainless steel
banding and clamping devices used in a variety of industrial and
commercial applications
Results
of Operations
The following is a discussion and analysis of our financial
position and results of operations for the period ended
March 31, 2010 and 2009. For purposes of this discussion
and analysis section, reference is made to the table below and
the Companys Condensed Consolidated Statements of
Operations included in Item 1.
Performance
in the Three Months Ended March 31, 2010 Compared with the
Same Period of 2009
Sales in the three months ended March 31, 2010 were
$355.6 million, a 9% increase from the comparable period
last year. This increase reflects a 6% increase in organic sales
and 3% favorable foreign currency translation. Sales to
international customers represented approximately 47% of total
sales in the current period compared to 46% in the same period
in 2009.
16
Table of Contents
For the first quarter of 2010, Fluid & Metering
Technologies contributed 48 percent of sales and
46 percent of operating income; Health & Science
Technologies accounted for 25 percent of sales and
26 percent of operating income; Dispensing Equipment
accounted for 9 percent of sales and 9 percent of
operating income; and Fire & Safety/Diversified
Products represented 18 percent of sales and
19 percent of operating income.
Fluid & Metering Technologies sales of
$172.9 million for the three months ended March 31,
2010 increased $15.9 million, or 10% compared with 2009,
reflecting a 7% increase in organic growth and 3% favorable
foreign currency translation. The increase in organic growth was
driven by strong global growth in energy, water and waste water
markets. In the first quarter of 2010, organic sales increased
approximately 9% domestically and 6% internationally. Organic
business sales to customers outside the U.S. were
approximately 44% of total segment sales during the first
quarter of 2010 and 39% in 2009.
Health & Science Technologies sales of
$87.5 million increased $13.3 million, or 18% in the
first quarter of 2010 compared with 2009. This reflects a 17%
increase in organic growth and 1% of favorable foreign currency
translation. The increase in organic growth reflects market
strength across all Health & Science Technologies
products. In the first quarter of 2010, organic sales increased
12% domestically and 25% internationally. Organic business sales
to customers outside the U.S. were approximately 40% of
total segment sales in the first quarter of 2010, compared to
38% in 2009.
Dispensing Equipment sales of $33.6 million increased
$0.7 million, or 2% in the first quarter of 2010 compared
with 2009. This increase reflects 5% of favorable foreign
currency translation offset by a 3% decrease in organic growth.
The decrease in organic growth is due to continued market
softness in North America and Europe. In the first quarter of
2010, organic sales increased 3% domestically, primarily due to
a large replenishment project and decreased 6% internationally.
Organic sales to customers outside the U.S. were
approximately 61% of total segment sales in the first quarter of
2010, compared with 67% in the comparable quarter of 2009.
Fire & Safety/Diversified Products sales of
$63.4 million decreased $1.6 million, or 2% in the
first quarter of 2010 compared with 2009. This change reflects a
5% decrease in organic business volume, partially offset by 3%
favorable foreign currency translation. The change in organic
business reflects weakness in fire suppression, partially offset
by strength in rescue equipment and engineered band clamping
systems. In the first quarter of 2010, organic business sales
decreased 7% domestically and 3% internationally. Organic sales
to customers outside the U.S. were approximately 54% of
total segment sales in the first quarter of 2010, compared to
57% in 2009.
17
Table of Contents
Three Months |
||||||||
Ended March 31, | ||||||||
2010 | 2009 | |||||||
Fluid & Metering Technologies
|
||||||||
Net sales
|
$ | 172,877 | $ | 157,018 | ||||
Operating
income(1)
|
32,140 | 22,618 | ||||||
Operating margin
|
18.6 | % | 14.4 | % | ||||
Depreciation and amortization
|
$ | 8,022 | $ | 7,769 | ||||
Capital expenditures
|
3,608 | 2,557 | ||||||
Health & Science Technologies
|
||||||||
Net sales
|
$ | 87,522 | $ | 74,188 | ||||
Operating
income(1)
|
18,552 | 9,850 | ||||||
Operating margin
|
21.2 | % | 13.3 | % | ||||
Depreciation and amortization
|
$ | 3,515 | $ | 3,513 | ||||
Capital expenditures
|
1,464 | 1,262 | ||||||
Dispensing Equipment
|
||||||||
Net sales
|
$ | 33,554 | $ | 32,873 | ||||
Operating
income(1)
|
6,639 | 3,979 | ||||||
Operating margin
|
19.8 | % | 12.1 | % | ||||
Depreciation and amortization
|
$ | 1,033 | $ | 784 | ||||
Capital expenditures
|
213 | 218 | ||||||
Fire & Safety/Diversified Products
|
||||||||
Net sales
|
$ | 63,401 | $ | 64,982 | ||||
Operating
income(1)
|
13,071 | 13,571 | ||||||
Operating margin
|
20.6 | % | 20.9 | % | ||||
Depreciation and amortization
|
$ | 1,452 | $ | 1,280 | ||||
Capital expenditures
|
864 | 822 | ||||||
Company
|
||||||||
Net sales
|
$ | 355,598 | $ | 326,613 | ||||
Operating
income(1)
|
57,893 | 39,161 | ||||||
Operating margin
|
16.3 | % | 12.0 | % | ||||
Depreciation and
amortization(2)
|
$ | 14,284 | $ | 13,594 | ||||
Capital expenditures
|
7,350 | 5,152 |
(1) | Group operating income excludes unallocated corporate operating expenses. | |
(2) | Excludes amortization of debt issuance expenses. |
Gross profit of $147.5 million in the first quarter of 2010
increased $24.3 million, or 20% from 2009. Gross profit as
a percent of sales was 41.5% in the first quarter of 2010 and
37.7% in 2009. The increase in gross margin primarily reflects
higher volume and product mix.
Selling, general and administrative (SG&A)
expenses increased to $87.8 million in the first quarter of
2010 from $81.8 million in 2009. The increase primarily
reflects higher volume related expenses. As a percent of sales,
SG&A expenses were 24.7% for 2010 and 25.0% for 2009.
During the three months ended March 31, 2010, the Company
recorded pre-tax restructuring expenses totaling
$1.9 million, while $2.3 million was recorded for the
same period in 2009. These restructuring expenses were mainly
attributable to employee severance related to employee
reductions across various functional areas and facility closures
resulting from the Companys cost savings initiatives.
18
Table of Contents
Operating income of $57.9 million and operating margins of
16.3% in the first quarter of 2010 were up from the
$39.2 million and 12.0% recorded in 2009, primarily
reflecting an increase in volume, cost reductions due to our
restructuring initiatives and prior year acquisition related
charges. In the Fluid & Metering Technologies Segment,
operating income of $32.1 million and operating margins of
18.6% in the first quarter of 2010 were up from the
$22.6 million and 14.4% recorded in 2009 principally due to
higher sales, cost reduction initiatives and prior year
acquisition related charges. In the Health & Science
Technologies Segment, operating income of $18.6 million and
operating margins of 21.2% in the first quarter of 2010 were up
from the $9.9 million and 13.3% recorded in 2009 due to
higher volume, cost reduction initiatives and acquisition
related charges recorded in the first quarter of 2009. In the
Dispensing Equipment Segment, operating income of
$6.6 million and operating margins of 19.8% in the first
quarter of 2010 were up from the $4.0 million of operating
income and 12.1% recorded in 2009, due to cost reduction
initiatives and improved productivity. Operating income and
operating margins in the Fire & Safety/Diversified
Products Segment of $13.1 million and 20.6%, respectively,
were slightly lower than the $13.6 million and 20.9%
recorded in 2009.
Other income of $0.3 million in 2010 was higher than the
$0.2 million loss in 2009, due to favorable foreign
currency translation.
Interest expense decreased to $3.4 million in 2010 from
$4.8 million in 2009. The decrease was principally due to
lower debt levels.
The provision for income taxes is based upon estimated annual
tax rates for the year applied to federal, state and foreign
income. The provision for income taxes increased to
$18.1 million in the first quarter of 2010 compared to the
first quarter of 2009, which was $11.5 million. The
effective tax rate decreased to 33.1% for the first quarter of
2010 compared to 33.8% in the first quarter of 2009 due to the
mix of global pre-tax income among jurisdictions.
Net income for the current quarter of $36.6 million
increased from the $22.6 million earned in the first
quarter of 2009. Diluted earnings per share in the first quarter
of 2010 of $0.45 increased $0.17, or 60%, compared with the
first quarter of 2009.
Liquidity
and Capital Resources
At March 31, 2010, working capital was $300.9 million
and our current ratio was 2.6 to 1. Cash flows from operating
activities increased $9.5 million, or 54%, to
$27.1 million in the first three months of 2010 mainly due
to increased volume.
Cash flows provided by operations were more than adequate to
fund capital expenditures of $7.5 million and
$4.9 million in the first three months of 2010 and 2009,
respectively. Capital expenditures were generally for machinery
and equipment that improved productivity and tooling to support
the global sourcing initiatives, although a portion was for
business system technology and replacement of equipment and
facilities. Management believes that the Company has ample
capacity in its plants and equipment to meet expected needs for
future growth in the intermediate term.
The Company maintains a $600.0 million unsecured domestic,
multi-currency bank revolving Credit Facility, which expires on
December 21, 2011. At March 31, 2010 there was
$290.4 million outstanding under the Credit Facility and
outstanding letters of credit totaled approximately
$7.1 million. The net available borrowing under the Credit
Facility as of March 31, 2010, was approximately
$302.5 million. Interest is payable quarterly on the
outstanding borrowings at the bank agents reference rate.
Interest on borrowings based on LIBOR plus an applicable margin
is payable on the maturity date of the borrowing, or quarterly
from the effective date for borrowings exceeding three months.
The applicable margin is based on the Companys senior,
unsecured, long-term debt rating and can range from
24 basis points to 50 basis points. Based on the
Companys BBB rating at March 31, 2010, the applicable
margin was 40 basis points. An annual Credit Facility fee,
also based on the Companys credit rating, is currently
10 basis points and is payable quarterly.
At March 31, 2010 the Company has one interest rate
exchange agreement related to the Credit Facility. The interest
rate exchange agreement, expiring in January 2011, effectively
converted $250.0 million of floating-rate debt into
fixed-rate debt at an interest rate of 3.25%. The fixed rate
noted above is comprised of the fixed rate on the interest rate
exchange agreement and the Companys current margin of
40 basis points on the Credit Facility.
19
Table of Contents
On April 18, 2008, the Company completed a
$100.0 million unsecured senior bank term loan agreement
(Term Loan), with covenants consistent with the
existing Credit Facility and a maturity on December 21,
2011. At March 31, 2010, there was $90.0 million
outstanding under the Term Loan. Interest under the Term Loan is
based on the bank agents reference rate or LIBOR plus an
applicable margin and is payable at the end of the selected
interest period, but at least quarterly. The applicable margin
is based on the Companys senior, unsecured, long-term debt
rating and can range from 45 to 100 basis points. Based on
the Companys current debt rating, the applicable margin is
80 basis points. The Term Loan requires a repayment of
$7.5 million in April 2011, with the remaining balance due
on December 21, 2011. The Company used the proceeds from
the Term Loan to pay down existing debt outstanding under the
Credit Facility. At March 31, 2010 the Company has an
interest rate exchange agreement related to the Term Loan that
expires December 2011. With a current notional amount of
$90.0 million, the agreement effectively converted
$100.0 million of floating-rate debt into fixed-rate debt
at an interest rate of 4.00%. The fixed rate is comprised of the
fixed rate on the interest rate exchange agreement and the
Companys current margin of 80 basis points on the
Term Loan.
In March of 2010 the United States enacted two new laws relating
to healthcare. The enactment of the Patient Protection and
Affordable Care Act and the Health Care and Education
Reconciliation Act of 2010 has resulted in comprehensive health
care reform. The Company is currently evaluating the
requirements and effect of this new legislation and does not
expect it to have a material impact on the consolidated
financial position, results of operations or cash flows of the
Company.
On April 15, 2010, the Company entered into a forward
starting interest rate swap with a notional amount of
$300.0 million and an effective date of December 8,
2010 whereby the Company will pay fixed interest and will
receive floating rate interest based on LIBOR through the
termination date of December 8, 2020. This swap was entered
into in anticipation of the expected issuance of
$300.0 million of new debt during the fourth quarter of
2010 and is designed to lock in the current market interest rate.
We believe for the next 12 months that cash flow from
operations and our availability under the Credit Facility will
be sufficient to meet our operating requirements, interest on
all borrowings, required debt repayments, any authorized share
repurchases, planned capital expenditures, and annual dividend
payments to holders of common stock. In the event that suitable
businesses are available for acquisition upon terms acceptable
to the Board of Directors, we may obtain all or a portion of the
financing for the acquisitions through the incurrence of
additional long-term borrowings.
Item 3. | Quantitative and Qualitative Disclosures About Market Risk. |
The Company is subject to market risk associated with changes in
foreign currency exchange rates and interest rates. We may, from
time to time, enter into foreign currency forward contracts and
interest rate swaps on our debt when we believe there is a
financial advantage in doing so. A treasury risk management
policy, adopted by the Board of Directors, describes the
procedures and controls over derivative financial and commodity
instruments, including foreign currency forward contracts and
interest rate swaps. Under the policy, we do not use derivative
financial or commodity instruments for trading purposes, and the
use of these instruments is subject to strict approvals by
senior officers. Typically, the use of derivative instruments is
limited to foreign currency forward contracts and interest rate
swaps on the Companys outstanding long-term debt. The
Companys exposure related to derivative instruments is, in
the aggregate, not material to its financial position, results
of operations or cash flows.
The Companys foreign currency exchange rate risk is
limited principally to the Euro, British Pound, Canadian Dollar
and Chinese Renminbi. We manage our foreign exchange risk
principally through invoicing our customers in the same currency
as the source of our products. The effect of transaction gains
and losses is reported within Other income
(expense)-net on the Condensed Consolidated Statements of
Operations.
The Companys interest rate exposure is primarily related
to the $385.7 million of total debt outstanding at
March 31, 2010. The majority of the debt is priced at
interest rates that float with the market. In order to mitigate
this interest exposure, the Company entered into interest rate
exchange agreements that effectively converted
$340.0 million of our floating-rate debt outstanding at
March 31, 2010 to a fixed-rate. A 50-basis point movement
in the interest rate on the remaining $45.7 million
floating-rate debt would result in an approximate
$0.2 million annualized increase or decrease in interest
expense and cash flows.
20
Table of Contents
Item 4. | Controls and Procedures. |
The Company maintains disclosure controls and procedures that
are designed to ensure that information required to be disclosed
in the Companys Exchange Act reports is recorded,
processed, summarized and reported within the time periods
specified in the SECs rules and forms, and that such
information is accumulated and communicated to the
Companys management, including its Chief Executive Officer
and Chief Financial Officer, as appropriate, to allow timely
decisions regarding required disclosure. In designing and
evaluating the disclosure controls and procedures, management
recognized that any controls and procedures, no matter how well
designed and operated, can provide only reasonable assurance of
achieving the desired control objectives, and management is
required to apply its judgment in evaluating the cost-benefit
relationship of possible controls and procedures.
As required by SEC
Rule 13a-15(b),
the Company carried out an evaluation, under the supervision and
with the participation of the Companys management,
including the Companys Chief Executive Officer and the
Companys Chief Financial Officer, of the effectiveness of
the design and operation of the Companys disclosure
controls and procedures as of the end of the period covered by
this report. Based on the foregoing, the Companys Chief
Executive Officer and Chief Financial Officer concluded that the
Companys disclosure controls and procedures were effective
to accomplish their objectives at the reasonable assurance level.
There has been no change in the Companys internal controls
over financial reporting during the Companys most recent
fiscal quarter that has materially affected, or is reasonably
likely to materially affect, the Companys internal
controls over financial reporting.
PART II.
OTHER INFORMATION
Item 1. | Legal Proceedings. |
The Company and six of its subsidiaries are presently named as
defendants in a number of lawsuits claiming various
asbestos-related personal injuries, allegedly as a result of
exposure to products manufactured with components that contained
asbestos. Such components were acquired from third party
suppliers, and were not manufactured by any of the subsidiaries.
To date, the majority of the Companys settlements and
legal costs, except for costs of coordination, administration,
insurance investigation and a portion of defense costs, have
been covered in full by insurance subject to applicable
deductibles. However, the Company cannot predict whether and to
what extent insurance will be available to continue to cover
such settlements and legal costs, or how insurers may respond to
claims that are tendered to them.
Claims have been filed in jurisdictions throughout the United
States. Most of the claims resolved to date have been dismissed
without payment. The balance have been settled for various
insignificant amounts. Only one case has been tried, resulting
in a verdict for the Companys business unit.
No provision has been made in the financial statements of the
Company, other than for insurance deductibles in the ordinary
course, and the Company does not currently believe the
asbestos-related claims will have a material adverse effect on
the Companys business, financial position, results of
operations or cash flow.
The Company is also party to various other legal proceedings
arising in the ordinary course of business, none of which is
expected to have a material adverse effect on its business,
financial condition, results of operations or cash flow.
21
Table of Contents
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds. |
Total Number of |
Maximum Dollar |
|||||||||||||||
Shares Purchased as |
Value that May Yet |
|||||||||||||||
Part of Publicly |
be Purchased |
|||||||||||||||
Total Number of |
Average Price |
Announced Plans |
Under the Plans |
|||||||||||||
Period
|
Shares Purchased | Paid per Share | or Programs(1) | or Programs(1) | ||||||||||||
January 1, 2010 to January 31, 2010 |
| | | $ | 75,000,020 | |||||||||||
February 1, 2010 to February 28, 2010 |
| | | $ | 75,000,020 | |||||||||||
March 1, 2010 to March 31, 2010 |
| | | $ | 75,000,020 | |||||||||||
Total
|
| | | $ | 75,000,020 | |||||||||||
(1) | On April 21, 2008, IDEXs Board of Directors authorized the repurchase of up to $125.0 million of its outstanding common shares either in the open market or through private transactions. |
Item 5. | Other Information. |
There has been no material change to the procedures by which
security holders may recommend nominees to the Companys
board.
Item 6. | Exhibits. |
The exhibits listed in the accompanying
Exhibit Index are filed as part of this report.
22
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
IDEX Corporation
/s/ Dominic
A. Romeo
Dominic A. Romeo
Vice President and Chief Financial Officer
(duly authorized principal financial officer)
/s/ Michael
J. Yates
Michael J. Yates
Vice President and Chief Accounting Officer
(duly authorized principal accounting officer)
May 4, 2010
23
Table of Contents
EXHIBIT INDEX
Exhibit |
||||
Number
|
Description
|
|||
3 | .1 | Restated Certificate of Incorporation of IDEX Corporation (formerly HI, Inc.) (incorporated by reference to Exhibit No. 3.1 to the Registration Statement on Form S-1 of IDEX, et al., Registration No. 33-21205, as filed on April 21, 1988) | ||
3 | .1(a) | Amendment to Restated Certificate of Incorporation of IDEX Corporation (formerly HI, Inc.), (incorporated by reference to Exhibit No. 3.1(a) to the Quarterly Report of IDEX on Form 10-Q for the quarter ended March 31, 1996, Commission File No. 1-10235) | ||
3 | .1(b) | Amendment to Restated Certificate of Incorporation of IDEX Corporation (incorporated by reference to Exhibit No. 3.1(b) to the Current Report of IDEX on Form 8-K dated March 24, 2005, Commission File No. 1-10235) | ||
3 | .2 | Amended and Restated By-Laws of IDEX Corporation (incorporated by reference to Exhibit No. 3.2 to Post-Effective Amendment No. 2 to the Registration Statement on Form S-1 of IDEX, et al., Registration No. 33-21205, as filed on July 17, 1989) | ||
3 | .2(a) | Amended and Restated Article III, Section 13 of the Amended and Restated By-Laws of IDEX Corporation (incorporated by reference to Exhibit No. 3.2(a) to Post-Effective Amendment No. 3 to the Registration Statement on Form S-1 of IDEX, et al., Registration No. 33-21205, as filed on February 12, 1990) | ||
4 | .1 | Restated Certificate of Incorporation and By-Laws of IDEX Corporation (filed as Exhibits No. 3.1 through 3.2(a)) | ||
4 | .2 | Specimen Certificate of Common Stock of IDEX Corporation (incorporated by reference to Exhibit No. 4.3 to the Registration Statement on Form S-2 of IDEX, et al., Registration No. 33-42208, as filed on September 16, 1991) | ||
4 | .3 | Credit Agreement, dated as of December 21, 2006, among IDEX Corporation, Bank of America N.A. as Agent and Issuing Bank, and the other financial institutions party hereto (incorporated by reference to Exhibit No. 10.1 to the Current Report of IDEX on Form 8-K dated December 22, 2006, Commission File No. 1-10235) | ||
4 | .3(a) | Amendment No. 2 to Credit Agreement, dated as of September 29, 2008, among IDEX Corporation, Bank of America N.A. as Agent and Issuing Bank, and the other financial institutions party hereto (incorporated by reference to Exhibit No. 4.3(a) to the Quarterly Report of IDEX on Form 10-Q for the quarter ended September 30, 2008, Commission File No. 1-10235) | ||
4 | .4 | Term Loan Agreement, dated April 18, 2008, among IDEX Corporation, Bank of America N.A. as Agent, and the other financial institutions party hereto (incorporated by reference to Exhibit No. 10.1 to the Current Report of IDEX on Form 8-K dated April 18, 2008, Commission File No. 1-10235) | ||
*31 | .1 | Certification of Chief Executive Officer Pursuant to Rule 13a-14(a) or Rule 15d-14(a) | ||
*31 | .2 | Certification of Chief Financial Officer Pursuant to Rule 13a-14(a) or Rule 15d-14(a) | ||
*32 | .1 | Certification pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code | ||
*32 | .2 | Certification pursuant to Section 1350 of Chapter 63 of Title 18 of the United States Code |
* | Filed herewith |
24